Wednesday, September 30, 2020
Financing and M&A

Amgen Announces Additional Investment of $421M In BeiGene

Amgen (NASDAQ:AMGN) today announced an additional investment of approximately $421 million in BeiGene’s registered direct offering of ordinary shares, which maintains Amgen’s current pro rata ownership of BeiGene at approximately 20.3%.  This additional investment reflects Amgen’s confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world’s second largest pharmaceutical market.  

Leave a Reply

Your email address will not be published.